Literature DB >> 28848933

Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation.

Gulshan Sharma1, Donald A Mahler2, Valerie M Mayorga3, Kathleen L Deering3, Oing Harshaw3, Vaidyanathan Ganapathy4.   

Abstract

Background: Low peak inspiratory flow rate (PIFR) (<60 L/min) among patients with chronic obstructive pulmonary disease (COPD) may result in ineffective medication inhalation, leading to poor bronchodilation. Objective: The objectives of this analysis were to evaluate the prevalence of low PIFR at the time of discharge from a COPD-related hospitalization and to examine the real-world treatment patterns and rehospitalizations by PIFR.
Methods: Patients at 7 sites in the United States were screened for enrollment at hospital discharge. PIFR was measured using the InCheckTM DIAL to simulate resistance of the DISKUS® dry powder inhaler (DPI). An equal number of patients were enrolled into low PIFR (<60 L/min) or normal PIFR (≥60 L/min) cohorts. Demographics, COPD-related clinical characteristics, health status, treatment and rehospitalization data were collected.
Results: Mean PIFR was 71±22.12 L/min among 268 screened patients; 31.7% (n=85) of patients had low PIFR. Among all enrolled patients (n=170), the low PIFR cohort was older (66.2±10.04 years versus 62.1±9.41 years, p=0.006) and more likely to be female (61.2% versus 42.4%, p=0.014). There was an increase in DPI use at discharge, compared with admission, in the low PIFR cohort (62.4% versus 70.6%, p=0.020). The incidences of all-cause rehospitalization up to 180 days were similar between the low and normal PIFR cohorts. Conclusions: At discharge following hospitalization for an exacerbation of COPD, approximately one-third of patients had a PIFR <60 L/min. More patients with a low PIFR were discharged with a DPI medication compared with use at admission. There was no difference in the rehospitalization rates by PIFR.

Entities:  

Keywords:  PIFR; chronic obstructive pulmonary disease; copd; discharge planning; exacerbation; outcomes research; peak inspiratory flow rate

Year:  2017        PMID: 28848933      PMCID: PMC5556913          DOI: 10.15326/jcopdf.4.3.2017.0183

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  15 in total

Review 1.  Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers.

Authors:  R Pauwels; S Newman; L Borgström
Journal:  Eur Respir J       Date:  1997-09       Impact factor: 16.671

Review 2.  Dry powder inhalers: an overview.

Authors:  Paul J Atkins
Journal:  Respir Care       Date:  2005-10       Impact factor: 2.258

Review 3.  Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.

Authors:  David E Geller
Journal:  Respir Care       Date:  2005-10       Impact factor: 2.258

4.  Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

Authors:  Donald A Mahler; Laurie A Waterman; Joseph Ward; Alex H Gifford
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-06-08       Impact factor: 2.849

5.  Inhaled therapy in elderly COPD patients; time for re-evaluation?

Authors:  Sheba Jarvis; Philip W Ind; Robert J Shiner
Journal:  Age Ageing       Date:  2007-01-31       Impact factor: 10.668

6.  Peak inspiratory flow through diskus and turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL).

Authors:  J van der Palen
Journal:  Respir Med       Date:  2003-03       Impact factor: 3.415

Review 7.  Drug delivery to the lungs from dry powder inhalers.

Authors:  Stephen P Newman
Journal:  Curr Opin Pulm Med       Date:  2003-04       Impact factor: 3.155

8.  The usefulness of inspiratory flow rate during inhalation corticosteroid therapy in asthma.

Authors:  Masashi Banno; Hidenori Ibata; Takashi Niimi; Shigeki Sato; Ryo Matsushita
Journal:  Respiration       Date:  2009-05-19       Impact factor: 3.580

9.  Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?

Authors:  Raid A M Al-Showair; Walid Y Tarsin; Khaled H Assi; Stanley B Pearson; Henry Chrystyn
Journal:  Respir Med       Date:  2007-07-12       Impact factor: 3.415

Review 10.  Use of Respimat Soft Mist inhaler in COPD patients.

Authors:  Paula Anderson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more
  33 in total

1.  Current Understanding of the Equivalence Evaluations for In Vitro Tests on Generic Dry Powder Inhaler Drug Products in Japan.

Authors:  Ryosuke Kuribayashi; Aya Myoenzono; Kazunori Takagi; Mitsue Hirota
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

2.  Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate.

Authors:  Chee H Loh; Jill A Ohar
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-14

Review 3.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

4.  High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study.

Authors:  Donald A Mahler; Shaban Demirel; Ramon Hollander; Gokul Gopalan; Asif Shaikh; Cathy D Mahle; Jessica Elder; Curtis Morrison
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

5.  Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study.

Authors:  Brendan Clark; Brian J Wells; Amit K Saha; Jessica Franchino-Elder; Asif Shaikh; Bonnie M K Donato; Jill A Ohar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-29

6.  Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD.

Authors:  Alexander G Duarte; Leon Tung; Wei Zhang; En Shuo Hsu; Yong-Fang Kuo; Gulshan Sharma
Journal:  Chronic Obstr Pulm Dis       Date:  2019-07-24

7.  Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.

Authors:  Donald A Mahler; Jill A Ohar; Chris N Barnes; Edmund J Moran; Srikanth Pendyala; Glenn D Crater
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

8.  Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial.

Authors:  Jianlan Hua; Wei Zhang; Hui-Fang Cao; Chun-Ling Du; Jia-Yun Ma; Yi-Hui Zuo; Jing Zhang
Journal:  BMJ Open       Date:  2020-05-07       Impact factor: 2.692

9.  Peak-Inspiratory-Flow-Rate Guided Inhalation Therapy Reduce Severe Exacerbation of COPD.

Authors:  Shih-Yu Chen; Chun-Kai Huang; Hui-Chuan Peng; Hsing-Chen Tsai; Szu-Ying Huang; Chong-Jen Yu; Jung-Yien Chien
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

Review 10.  Nebulized Therapies in COPD: Past, Present, and the Future.

Authors:  Igor Z Barjaktarevic; Aaron P Milstone
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.